-Bloomberg
Junshi Biosciences – Coherus Toripalimab Chemo Combo Met Survival Endpoints In Lung Cancer Setting
Shanghai Junshi Biosciences Co Ltd and Coherus BioSciences Inc (NASDAQ:CHRS) have shared biomarker analyses from the CHOICE-01 Phase 3 trial of toripalimab plus…